{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-21-000018","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.057432+00:00","generated_at":"2026-06-30T01:19:21.112012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q2 2021 revenue $6.2B (+21% YoY); GAAP EPS $1.21, non-GAAP EPS $1.87; raises Veklury guidance","bullets":["Total Q2 revenue $6.2B (+21% YoY); product sales ex-Veklury $5.3B (+5%).","GAAP diluted EPS $1.21 (vs. loss of $2.66); non-GAAP diluted EPS $1.87 (+68%).","Veklury sales $829M; HIV sales $3.9B (-2%); Biktarvy up 24%; HCV up 23%.","FY2021 guidance: product sales $24.4-25.0B; Veklury $2.7-3.1B (prev $2.0-3.0B); non-GAAP EPS $6.90-7.25.","Quarterly dividend $0.71 payable Sep 29, record Sep 15; pipeline updates include lenacapavir NDA filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-21-000018","json":"https://secwatch.observer/filing/0000882095-21-000018.json","markdown":"https://secwatch.observer/filing/0000882095-21-000018.md","text":"https://secwatch.observer/filing/0000882095-21-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000018/0000882095-21-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000018/gild-20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:19:21.112012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}